Pulmonary Valve Disease malady

Categories: Cardiovascular diseases

Aliases & Classifications for Pulmonary Valve Disease

Aliases & Descriptions for Pulmonary Valve Disease:

Name: Pulmonary Valve Disease 12 14
Pulmonary Valve Disorder 12 29 69


External Ids:

Disease Ontology 12 DOID:5749
ICD9CM 35 424.3
NCIt 47 C78579
SNOMED-CT 64 195001000 76267008
ICD10 33 I37 I39.3
UMLS 69 C0034087

Summaries for Pulmonary Valve Disease

MalaCards based summary : Pulmonary Valve Disease, also known as pulmonary valve disorder, is related to rheumatic pulmonary valve disease and atrial septal defect 9. An important gene associated with Pulmonary Valve Disease is NKX2-6 (NK2 Homeobox 6), and among its related pathways/superpathways are DREAM Repression and Dynorphin Expression and Development FGFR signaling pathway. The drugs Warfarin and Benzocaine have been mentioned in the context of this disorder. Related phenotypes are shRNA abundance <= 50% and cardiovascular system

Related Diseases for Pulmonary Valve Disease

Diseases in the Pulmonary Valve Disease family:

Pulmonary Valve Insufficiency

Diseases related to Pulmonary Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
id Related Disease Score Top Affiliating Genes
1 rheumatic pulmonary valve disease 12.1
2 atrial septal defect 9 10.8
3 pulmonary valve insufficiency 10.8
4 pseudomonas stutzeri infections 10.2 PTPN11 SOS1
5 rdh12-related leber congenital amaurosis 10.1 PTPN11 SOS1
6 ascending cholangitis 10.1 NKX2-6 SLC6A11
7 hyperproinsulinemia 10.1 PTPN11 SOS1
8 pulmonary valve stenosis 10.1
9 paget disease, extramammary 10.0 CRELD1 NKX2-6
10 right inferior vena cava connecting to left-sided atrium 10.0 CRELD1 GATA4
11 left superior vena cava persisting to left-sided atrium 10.0 CRELD1 GATA4
12 huriez syndrome 10.0 CRELD1 NKX2-6
13 pericardium disease 10.0 CRELD1 GATA6 NKX2-6
14 fetal alcohol syndrome 10.0 GATA4 GATA6 NKX2-6
15 testicular germ cell tumor non-seminomatous 9.9 CRELD1 NKX2-6 SLC6A11
16 persistent eustachian valve 9.9 CRELD1 GATA4 GATA6
17 congenital benign spinal muscular atrophy dominant 9.9 CRELD1 GATA4 GATA6
18 pauciarticular chronic arthritis 9.9 CRELD1 GATA4 GATA6
19 macroglossia 9.9 CRELD1 GATA4 NKX2-6
20 chromosome 15q11-q13 duplication syndrome 9.9 PTPN11 SOS1 SPRED1
21 malignant pineal area germ cell neoplasm 9.9 GATA4 GATA6 NKX2-6 TBX5
22 leopard syndrome 3 9.9 PTPN11 SOS1 SPRED1
23 dentine erosion 9.9 GATA4 GATA6 NKX2-6 TBX5
24 nephrolithiasis 9.9 PTPN11 SPRED1
25 metachondromatosis 9.8 PTPN11 SOS1 SPRED1
26 trichodental syndrome 9.8 CRELD1 GATA4 GATA6 NKX2-6
27 xanthogranulomatous pyelonephritis 9.8 GATA4 NKX2-6 PTPN11 TBX5
28 hypogonadotropic hypogonadism 12 with or without anosmia 9.8 CRELD1 GATA4 GATA6 NKX2-6
29 cardiomyopathy, dilated, 1r 9.8 PTPN11 SPRED1
30 partial fetal alcohol syndrome 9.6 CRELD1 GATA4 GATA6 NKX2-6 TBX5
31 optic nerve disease 9.6 CRELD1 GATA4 GATA6 NKX2-6 TBX5
32 ichthyosis 9.6 CRELD1 GATA4 GATA6 NKX2-6 TBX5
33 carcinoid syndrome 9.6
34 ceroid lipofuscinosis, neuronal, 8 9.5 CRELD1 GATA4 GATA6 NKX2-6 PTPN11 TBX5
35 vulvar apocrine adenocarcinoma 9.2 CRELD1 GATA4 NKX2-6 PTPN11 SOS1 SPRED1
36 vulvar sebaceous carcinoma 8.7 CRELD1 GATA4 GATA6 NKX2-6 PTPN11 SLC6A11

Comorbidity relations with Pulmonary Valve Disease via Phenotypic Disease Network (PDN): (show all 15)

Acute Cystitis Chronic Myocardial Ischemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Intermediate Coronary Syndrome Ischemic Heart Disease
Left Ventricular Outflow Tract Obstruction Mitral Valve Disease
Pulmonary Hypertension, Familial Primary, 1, with or Without Hht Respiratory Failure
Sinoatrial Node Disease Transient Cerebral Ischemia
Tricuspid Valve Disease

Graphical network of the top 20 diseases related to Pulmonary Valve Disease:

Diseases related to Pulmonary Valve Disease

Symptoms & Phenotypes for Pulmonary Valve Disease

GenomeRNAi Phenotypes related to Pulmonary Valve Disease according to GeneCards Suite gene sharing:

id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.17 GATA4 GATA6 PTPN11 SLC6A11 SOS1 TAB2

MGI Mouse Phenotypes related to Pulmonary Valve Disease:

id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 GATA4 GATA6 NKX2-6 PTPN11 SOS1 TAB2
2 embryo MP:0005380 9.87 GATA4 GATA6 NKX2-6 PTPN11 SOS1 TAB2
3 mortality/aging MP:0010768 9.76 TAB2 TBX5 GATA4 GATA6 NKX2-6 PTPN11
4 limbs/digits/tail MP:0005371 9.65 GATA4 GATA6 PTPN11 SPRED1 TBX5
5 muscle MP:0005369 9.35 GATA4 GATA6 PTPN11 SOS1 TBX5
6 respiratory system MP:0005388 9.02 GATA4 GATA6 NKX2-6 PTPN11 SPRED1

Drugs & Therapeutics for Pulmonary Valve Disease

Drugs for Pulmonary Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 314)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Warfarin Approved Phase 4,Phase 2,Phase 3 81-81-2 6691 54678486
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
Dobutamine Approved Phase 4 34368-04-2 36811
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
Remifentanil Approved Phase 4,Phase 2 132875-61-7 60815
Bupivacaine Approved, Investigational Phase 4,Phase 2 2180-92-9, 38396-39-3 2474
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Phenprocoumon Approved Phase 4 435-97-2 9908 54680692
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
Menadione Approved, Nutraceutical Phase 4,Phase 2,Phase 3 58-27-5 4055
14 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
Phytonadione Approved, Nutraceutical Phase 4,Phase 2,Phase 3 84-80-0 4812 5284607
16 Sildenafil Citrate Phase 4,Phase 3,Phase 2 171599-83-0
17 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1
19 Serine Proteinase Inhibitors Phase 4,Phase 2,Phase 3
20 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Adrenergic Agonists Phase 4,Phase 3,Phase 2
22 Coagulants Phase 4,Phase 2,Phase 3
23 Adrenergic beta-Agonists Phase 4,Phase 3
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
26 Hemostatics Phase 4,Phase 2,Phase 3
27 Trace Elements Phase 4,Phase 2,Phase 3
28 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Anesthetics, General Phase 4,Phase 3,Phase 2
30 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
34 Vitamins Phase 4,Phase 2,Phase 3
35 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2
36 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
37 Anticoagulants Phase 4,Phase 2,Phase 3,Early Phase 1
38 Protective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
39 Antifibrinolytic Agents Phase 4,Phase 2,Phase 3
40 Micronutrients Phase 4,Phase 2,Phase 3
41 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Early Phase 1
Lactitol Phase 4 585-86-4 3871
43 Atorvastatin Calcium Phase 4 134523-03-8
44 diuretics Phase 4,Phase 3,Phase 1
45 Chelating Agents Phase 4,Early Phase 1
46 Cholinergic Agents Phase 4,Phase 3,Phase 2
47 Narcotics Phase 4,Phase 2
48 Natriuretic Agents Phase 4,Phase 3,Phase 1
49 Natriuretic Peptide, Brain Phase 4,Phase 3
50 Analgesics, Opioid Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 519)
id Name Status NCT ID Phase
1 The Study of Warfarin Maintenance Dose in Chinese Patients Unknown status NCT01855737 Phase 4
2 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
3 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
4 Physiological Response to Heliox21 and Air O2 Unknown status NCT01498432 Phase 4
5 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
6 Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair Unknown status NCT00339053 Phase 4
7 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
8 Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease Completed NCT00862043 Phase 4
9 Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis Completed NCT01060020 Phase 4
10 Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis Completed NCT00222534 Phase 4
11 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients Completed NCT01996124 Phase 4
12 Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation Completed NCT02454582 Phase 4
13 Effects of Remifentanil on Respiratory Function in Mechanically Ventilated Patients Completed NCT00665119 Phase 4
14 Brain Natriuretic Peptide (BNP) Levels in Patients in Non Invasive Mechanical Ventilation Completed NCT00453726 Phase 4
15 B-type Natriuretic Peptide (BNP)-Guided Diagnostic Strategy in Intensive Care Unit (ICU) Patients With Respiratory Failure Completed NCT00130559 Phase 4
16 Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure Completed NCT00686257 Phase 4
17 Statin Therapy In Atrial Refractoriness and Reperfusion Injury Completed NCT01780740 Phase 4
18 Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm Completed NCT00511173 Phase 4
19 General Plus Spinal Anesthesia and General Anesthesia Alone on Right Ventricular Function Recruiting NCT03013075 Phase 4
20 Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study Recruiting NCT01275339 Phase 4
21 Acute Effect of EPAP and Noninvasive Ventilation on Pulmonary Function and Lung Regional Ventilation on Bariatric Surgery Recruiting NCT02577744 Phase 4
22 Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit Recruiting NCT02822001 Phase 4
23 PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension Recruiting NCT02378649 Phase 4
24 Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification Recruiting NCT02066662 Phase 4
25 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Active, not recruiting NCT02019264 Phase 4
26 COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction Not yet recruiting NCT02987387 Phase 4
27 Effect of Neuromuscular Blockade and Reversal on Breathing Not yet recruiting NCT02845375 Phase 4
28 The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement Suspended NCT01375335 Phase 4
29 Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study Terminated NCT01272388 Phase 4
30 Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure Terminated NCT00243828 Phase 4
31 Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy Terminated NCT01188369 Phase 4
32 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4
33 Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension Unknown status NCT01091012 Phase 3
34 Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease Unknown status NCT01013688 Phase 3
35 The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients Unknown status NCT01869205 Phase 3
36 Efficacy and Safety of Venus P-valve to Treat RVOT Stenosis With Pulmonary Regurgitation Unknown status NCT02071654 Phase 3
37 Hemofiltration for Respiratory Failure After Bone Marrow Transplantation Unknown status NCT00120575 Phase 2, Phase 3
38 Implantation of Endobronchial Valves Versus Intrabronchial Valves in Patients With Severe Heterogeneous Emphysema Unknown status NCT01457833 Phase 2, Phase 3
39 Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures Unknown status NCT01902732 Phase 2, Phase 3
40 Sequential Endoscopic Lung Volume Reduction Unknown status NCT00613860 Phase 3
41 Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency Unknown status NCT01357460 Phase 2, Phase 3
42 Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study Unknown status NCT00995852 Phase 2, Phase 3
43 SOLAR & ATRILAZE Atrial Fibrillation Trial Unknown status NCT00734058 Phase 3
44 Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation Unknown status NCT00691470 Phase 2, Phase 3
45 Glutamate for Metabolic Intervention in Coronary Surgery Unknown status NCT00489827 Phase 3
46 Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients Unknown status NCT00683124 Phase 3
47 Pulmonary Valve Replacement in Large Right Ventricular Outflow Tract Completed NCT00259207 Phase 3
48 Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients Completed NCT01621971 Phase 3
49 Broncho-alveolar Lavage Under Noninvasive Ventilation With Propofol TCI in Patient With AHRF Completed NCT00741949 Phase 3
50 Endobronchial Valve for Emphysema Palliation Trial (VENT) Completed NCT00129584 Phase 3

Search NIH Clinical Center for Pulmonary Valve Disease

Genetic Tests for Pulmonary Valve Disease

Genetic tests related to Pulmonary Valve Disease:

id Genetic test Affiliating Genes
1 Abnormality of the Pulmonary Valve 29

Anatomical Context for Pulmonary Valve Disease

Publications for Pulmonary Valve Disease

Articles related to Pulmonary Valve Disease:

id Title Authors Year
Importance of pulmonary valve disease during implantation of a biventricular assist device. ( 24268185 )
Tricuspid and pulmonary valve disease evaluation and management. ( 21070730 )
Pulmonary valve replacement: extending the indications to the whole spectrum of pulmonary valve disease. ( 19804205 )
Percutaneous stent-mounted valve for treatment of aortic or pulmonary valve disease. ( 15343576 )
Carcinoid syndrome: an unusual cause of tricuspid and pulmonary valve disease. ( 12876616 )
Rheumatic pulmonary valve disease. ( 11273310 )
Echocardiographic evaluation of isolated pulmonary valve disease in adolescents and adults. ( 10146329 )
Rheumatic pulmonary valve disease. ( 5380838 )

Variations for Pulmonary Valve Disease

Expression for Pulmonary Valve Disease

Search GEO for disease gene expression data for Pulmonary Valve Disease.

Pathways for Pulmonary Valve Disease

Pathways related to Pulmonary Valve Disease according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
Show member pathways
12.22 GATA4 GATA6 TAB2
Show member pathways
12.15 PTPN11 SOS1 TAB2
Show member pathways
11.93 PTPN11 SOS1 TAB2
Show member pathways
11.87 PTPN11 SOS1 SPRED1
Show member pathways
11.64 PTPN11 SOS1 SPRED1
Show member pathways
11.54 PTPN11 SOS1
Show member pathways
11.46 PTPN11 SOS1 SPRED1
8 11.28 PTPN11 SOS1
9 11.24 GATA4 GATA6
10 11.22 PTPN11 SOS1
11 11.18 PTPN11 SOS1
12 11.17 PTPN11 SOS1 TAB2
13 11.16 PTPN11 SOS1
14 11.06 PTPN11 SOS1
15 10.98 PTPN11 SOS1
Show member pathways
10.91 PTPN11 SOS1
17 10.82 PTPN11 SOS1
18 10.72 PTPN11 SOS1
19 10.59 GATA4 GATA6 PTPN11 TBX5

GO Terms for Pulmonary Valve Disease

Biological processes related to Pulmonary Valve Disease according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.56 NKX2-6 PTPN11 TAB2 TBX5
2 negative regulation of autophagy GO:0010507 9.51 GATA4 TAB2
3 positive regulation of BMP signaling pathway GO:0030513 9.49 GATA4 GATA6
4 ventricular septum development GO:0003281 9.48 GATA4 TBX5
5 positive regulation of cardiac muscle cell proliferation GO:0060045 9.46 GATA6 TBX5
6 neurotrophin TRK receptor signaling pathway GO:0048011 9.43 PTPN11 SOS1
7 atrial septum morphogenesis GO:0060413 9.4 GATA4 TBX5
8 pericardium development GO:0060039 9.37 NKX2-6 TBX5
9 cardiac muscle cell differentiation GO:0055007 9.33 GATA4 GATA6 TBX5
10 intestinal epithelial cell differentiation GO:0060575 9.32 GATA4 GATA6
11 endocardial cushion development GO:0003197 9.13 CRELD1 GATA4 TBX5
12 positive regulation of cardioblast differentiation GO:0051891 8.8 GATA4 GATA6 TBX5

Molecular functions related to Pulmonary Valve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.46 GATA4 GATA6 NKX2-6 TBX5
2 RNA polymerase II transcription factor binding GO:0001085 9.26 GATA4 GATA6
3 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.13 GATA4 GATA6 TBX5
4 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 8.8 GATA4 GATA6 TBX5

Sources for Pulmonary Valve Disease

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....